<Research>CICC Expects Commercial Insurance Innovative Drug Catalog Adjustments to Help High-Value Innovative Drugs Land
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Source: aastocks
Drug Catalog Adjustments: China's NHSA has announced the preliminary review of adjustments to drug catalogs for basic medical insurance, maternity insurance, work injury insurance, and commercial insurance, with 534 drugs passing the review. A dual catalog mechanism is expected to be implemented to differentiate between essential clinical drugs and high-value innovative drugs.
Investment Opportunities: CICC predicts that the expansion of commercial insurance will encourage investment in innovative drug R&D, benefiting companies like BEIGENE and others listed, as they focus on high-value drugs not covered by standard medical insurance.
Analyst Views on 00512
Wall Street analysts forecast 00512 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00512 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 7.900
Low
Averages
High
Current: 7.900
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
